BioNTech (BNTX) Competitors

GSK (NYSE:GSK) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

Do analysts prefer GSK or BNTX?

GSK presently has a consensus target price of $37.38, indicating a potential upside of 3.02%. BioNTech has a consensus target price of $136.58, indicating a potential upside of 24.14%. Given BioNTech's stronger consensus rating and higher possible upside, analysts plainly believe BioNTech is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.11
BioNTech	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.83

Is GSK or BNTX more profitable?

GSK has a net margin of 9.89% compared to BioNTech's net margin of -27.37%. GSK's return on equity of 48.82% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	9.89%	48.82%	11.15%
BioNTech	-27.37%	-3.94%	-3.41%

Do insiders and institutionals hold more shares of GSK or BNTX?

15.7% of GSK shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 10.0% of GSK shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Which has higher valuation & earnings, GSK or BNTX?

GSK has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$40.10B	1.85	$3.29B	$1.94	18.70
BioNTech	$2.98B	8.88	-$719.92M	-$3.40	-32.36

Does the media refer more to GSK or BNTX?

In the previous week, GSK had 23 more articles in the media than BioNTech. MarketBeat recorded 32 mentions for GSK and 9 mentions for BioNTech. BioNTech's average media sentiment score of 0.56 beat GSK's score of 0.45 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	10 Very Positive mention(s)	8 Positive mention(s)	4 Neutral mention(s)	5 Negative mention(s)	5 Very Negative mention(s)	Neutral
BioNTech	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, GSK or BNTX?

GSK has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500.

Summary

GSK beats BioNTech on 9 of the 16 factors compared between the two stocks.